Blog

In an increasingly complex clinical research environment, safeguarding patient safety while ensuring high-quality data has become more critical than ever. A new strategic alliance between Verified Clinical Trials (VCT) and Chubb aims to address both priorities head-on by introducing a more proactive, integrated approach to clinical trial risk management. This collaboration brings together two complementary

Momentum doesn’t announce itself. You just wake up one day and realize — it’s already here. There’s a particular feeling that comes when an industry finally catches up to a problem you’ve been solving for years. It’s not triumphant. It’s quieter than that. It’s the feeling of watching the conversation shift — of hearing the

Early-phase clinical trials are among the most critical stages in drug development. These studies lay the foundation for understanding safety, tolerability, pharmacokinetics, pharmacodynamics, and early clinical signals that can influence the entire future of a program. Because the stakes are so high, subject selection in early-phase research must be as strong and reliable as possible.

Clinical research is complex. Sponsors cannot control every variable in a clinical trial. Recruitment challenges.Patient adherence.Biologic variability.Unexpected safety signals. These are inherent realities of drug development. But there is one risk that can be controlled: Duplicate research subjects entering clinical trials. And yet, across the industry, this issue continues to compromise patient safety, study integrity,

Clinical trial protocols routinely state that subjects must be:Clinical trial protocols frequently require that subjects be naïve to the investigational product. That requirement was not placed there casually. It exists for two fundamental reasons: 1. Patient safety2. Study integrity If prior exposure to the compound can alter safety signals, PK/PD behavior, dose response, or endpoint